The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Kinase inhibitors are considered as specific enzymes that help in preventing the process of cell division and the growth of cancerous cells. The kinase inhibitors are easy to use and are handy while treating cancer patients by blocking the signals that alert the cancer cells to grow. With the help of research and development activities in the cancer treatments, several innovations, and advanced therapeutics have been introduced. However, the results of these drugs and treatments are considered partial, palliative, and unpredictable at times. As a result, the key players in the market are emphasizing on research activities in order to introduce effective drugs and treatments and restrict the rising incidence of cancer across the globe.
The research study offers a comprehensive analysis of the global kinase inhibitors market, highlighting the primary factors that are likely to encourage the growth of the overall market in the near future. In addition, with the assistance of analytical tools, the research study throws light on the key drivers, promising opportunities, and limitations in the global kinase inhibitors market. The product portfolio, primary applications, key geographical segments, and the competitive scenario of the global market have been provided in the research study to offer the readers with a strong understanding of the market. Moreover, the market share, size, and the anticipated growth rate of the leading product and application segments have been provided in the research study.
The global Kinase Inhibitors market was valued at US$ 52990 million in 2023 and is anticipated to reach US$ 73950 million by 2030, witnessing a CAGR of 4.4% during the forecast period 2024-2030.
North American market for Kinase Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Kinase Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Kinase Inhibitors in Oncology is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Kinase Inhibitors include Merck, Novartis, Pfizer, Sanofi, GlaxoSmithKline, Biogen Idec, Bayer Healthcare Pharmaceuticals, Johnson and Tolero Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Kinase Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kinase Inhibitors.
Report Scope
The Kinase Inhibitors market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Kinase Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Kinase Inhibitors companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
- Merck
- Novartis
- Pfizer
- Sanofi
- GlaxoSmithKline
- Biogen Idec
- Bayer Healthcare Pharmaceuticals
- Johnson
- Tolero Pharmaceutical
- Astellas Pharma Inc
- Eli Lilly and Co
- Incyte Corp
- AstraZeneca
- Bristol-Myers Squibb
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche Ltd
- Eisai Co., Ltd.
- BerGenBio
- Rigel Pharmaceuticals
- Mirati Therapeutics
Segment by Type
- Non-receptor Tyrosine Kinase Inhibitors
- Receptor Tyrosine Kinase Inhibitors
- Multikinase Inhibitors
- Serine/Threonine Kinase Inhibitors
- Protein Kinase C Inhibitors
- RHO Kinase Inhibitors
- Others
Segment by Application
- Oncology
- Inflammatory Diseases
- Others
By Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia)
- Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
- Latin America (Mexico, Brazil, Argentina)
- Middle East & Africa (Turkey, Saudi Arabia, UAE)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Kinase Inhibitors companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Kinase Inhibitors Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Non-receptor Tyrosine Kinase Inhibitors
1.2.3 Receptor Tyrosine Kinase Inhibitors
1.2.4 Multikinase Inhibitors
1.2.5 Serine/Threonine Kinase Inhibitors
1.2.6 Protein Kinase C Inhibitors
1.2.7 RHO Kinase Inhibitors
1.2.8 Others
1.3 Market by Application
1.3.1 Global Kinase Inhibitors Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Oncology
1.3.3 Inflammatory Diseases
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Kinase Inhibitors Market Perspective (2019-2030)
2.2 Kinase Inhibitors Growth Trends by Region
2.2.1 Global Kinase Inhibitors Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Kinase Inhibitors Historic Market Size by Region (2019-2024)
2.2.3 Kinase Inhibitors Forecasted Market Size by Region (2025-2030)
2.3 Kinase Inhibitors Market Dynamics
2.3.1 Kinase Inhibitors Industry Trends
2.3.2 Kinase Inhibitors Market Drivers
2.3.3 Kinase Inhibitors Market Challenges
2.3.4 Kinase Inhibitors Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Kinase Inhibitors Players by Revenue
3.1.1 Global Top Kinase Inhibitors Players by Revenue (2019-2024)
3.1.2 Global Kinase Inhibitors Revenue Market Share by Players (2019-2024)
3.2 Global Kinase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Kinase Inhibitors Revenue
3.4 Global Kinase Inhibitors Market Concentration Ratio
3.4.1 Global Kinase Inhibitors Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Kinase Inhibitors Revenue in 2023
3.5 Kinase Inhibitors Key Players Head office and Area Served
3.6 Key Players Kinase Inhibitors Product Solution and Service
3.7 Date of Enter into Kinase Inhibitors Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Kinase Inhibitors Breakdown Data by Type
4.1 Global Kinase Inhibitors Historic Market Size by Type (2019-2024)
4.2 Global Kinase Inhibitors Forecasted Market Size by Type (2025-2030)
5 Kinase Inhibitors Breakdown Data by Application
5.1 Global Kinase Inhibitors Historic Market Size by Application (2019-2024)
5.2 Global Kinase Inhibitors Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Kinase Inhibitors Market Size (2019-2030)
6.2 North America Kinase Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Kinase Inhibitors Market Size by Country (2019-2024)
6.4 North America Kinase Inhibitors Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Kinase Inhibitors Market Size (2019-2030)
7.2 Europe Kinase Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Kinase Inhibitors Market Size by Country (2019-2024)
7.4 Europe Kinase Inhibitors Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Kinase Inhibitors Market Size (2019-2030)
8.2 Asia-Pacific Kinase Inhibitors Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Kinase Inhibitors Market Size by Region (2019-2024)
8.4 Asia-Pacific Kinase Inhibitors Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Kinase Inhibitors Market Size (2019-2030)
9.2 Latin America Kinase Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Kinase Inhibitors Market Size by Country (2019-2024)
9.4 Latin America Kinase Inhibitors Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Kinase Inhibitors Market Size (2019-2030)
10.2 Middle East & Africa Kinase Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Kinase Inhibitors Market Size by Country (2019-2024)
10.4 Middle East & Africa Kinase Inhibitors Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Detail
11.1.2 Merck Business Overview
11.1.3 Merck Kinase Inhibitors Introduction
11.1.4 Merck Revenue in Kinase Inhibitors Business (2019-2024)
11.1.5 Merck Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Kinase Inhibitors Introduction
11.2.4 Novartis Revenue in Kinase Inhibitors Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Kinase Inhibitors Introduction
11.3.4 Pfizer Revenue in Kinase Inhibitors Business (2019-2024)
11.3.5 Pfizer Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Detail
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Kinase Inhibitors Introduction
11.4.4 Sanofi Revenue in Kinase Inhibitors Business (2019-2024)
11.4.5 Sanofi Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Detail
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Kinase Inhibitors Introduction
11.5.4 GlaxoSmithKline Revenue in Kinase Inhibitors Business (2019-2024)
11.5.5 GlaxoSmithKline Recent Development
11.6 Biogen Idec
11.6.1 Biogen Idec Company Detail
11.6.2 Biogen Idec Business Overview
11.6.3 Biogen Idec Kinase Inhibitors Introduction
11.6.4 Biogen Idec Revenue in Kinase Inhibitors Business (2019-2024)
11.6.5 Biogen Idec Recent Development
11.7 Bayer Healthcare Pharmaceuticals
11.7.1 Bayer Healthcare Pharmaceuticals Company Detail
11.7.2 Bayer Healthcare Pharmaceuticals Business Overview
11.7.3 Bayer Healthcare Pharmaceuticals Kinase Inhibitors Introduction
11.7.4 Bayer Healthcare Pharmaceuticals Revenue in Kinase Inhibitors Business (2019-2024)
11.7.5 Bayer Healthcare Pharmaceuticals Recent Development
11.8 Johnson
11.8.1 Johnson Company Detail
11.8.2 Johnson Business Overview
11.8.3 Johnson Kinase Inhibitors Introduction
11.8.4 Johnson Revenue in Kinase Inhibitors Business (2019-2024)
11.8.5 Johnson Recent Development
11.9 Tolero Pharmaceutical
11.9.1 Tolero Pharmaceutical Company Detail
11.9.2 Tolero Pharmaceutical Business Overview
11.9.3 Tolero Pharmaceutical Kinase Inhibitors Introduction
11.9.4 Tolero Pharmaceutical Revenue in Kinase Inhibitors Business (2019-2024)
11.9.5 Tolero Pharmaceutical Recent Development
11.10 Astellas Pharma Inc
11.10.1 Astellas Pharma Inc Company Detail
11.10.2 Astellas Pharma Inc Business Overview
11.10.3 Astellas Pharma Inc Kinase Inhibitors Introduction
11.10.4 Astellas Pharma Inc Revenue in Kinase Inhibitors Business (2019-2024)
11.10.5 Astellas Pharma Inc Recent Development
11.11 Eli Lilly and Co
11.11.1 Eli Lilly and Co Company Detail
11.11.2 Eli Lilly and Co Business Overview
11.11.3 Eli Lilly and Co Kinase Inhibitors Introduction
11.11.4 Eli Lilly and Co Revenue in Kinase Inhibitors Business (2019-2024)
11.11.5 Eli Lilly and Co Recent Development
11.12 Incyte Corp
11.12.1 Incyte Corp Company Detail
11.12.2 Incyte Corp Business Overview
11.12.3 Incyte Corp Kinase Inhibitors Introduction
11.12.4 Incyte Corp Revenue in Kinase Inhibitors Business (2019-2024)
11.12.5 Incyte Corp Recent Development
11.13 AstraZeneca
11.13.1 AstraZeneca Company Detail
11.13.2 AstraZeneca Business Overview
11.13.3 AstraZeneca Kinase Inhibitors Introduction
11.13.4 AstraZeneca Revenue in Kinase Inhibitors Business (2019-2024)
11.13.5 AstraZeneca Recent Development
11.14 Bristol-Myers Squibb
11.14.1 Bristol-Myers Squibb Company Detail
11.14.2 Bristol-Myers Squibb Business Overview
11.14.3 Bristol-Myers Squibb Kinase Inhibitors Introduction
11.14.4 Bristol-Myers Squibb Revenue in Kinase Inhibitors Business (2019-2024)
11.14.5 Bristol-Myers Squibb Recent Development
11.15 Boehringer Ingelheim International GmbH
11.15.1 Boehringer Ingelheim International GmbH Company Detail
11.15.2 Boehringer Ingelheim International GmbH Business Overview
11.15.3 Boehringer Ingelheim International GmbH Kinase Inhibitors Introduction
11.15.4 Boehringer Ingelheim International GmbH Revenue in Kinase Inhibitors Business (2019-2024)
11.15.5 Boehringer Ingelheim International GmbH Recent Development
11.16 F. Hoffmann-La Roche Ltd
11.16.1 F. Hoffmann-La Roche Ltd Company Detail
11.16.2 F. Hoffmann-La Roche Ltd Business Overview
11.16.3 F. Hoffmann-La Roche Ltd Kinase Inhibitors Introduction
11.16.4 F. Hoffmann-La Roche Ltd Revenue in Kinase Inhibitors Business (2019-2024)
11.16.5 F. Hoffmann-La Roche Ltd Recent Development
11.17 Eisai Co., Ltd.
11.17.1 Eisai Co., Ltd. Company Detail
11.17.2 Eisai Co., Ltd. Business Overview
11.17.3 Eisai Co., Ltd. Kinase Inhibitors Introduction
11.17.4 Eisai Co., Ltd. Revenue in Kinase Inhibitors Business (2019-2024)
11.17.5 Eisai Co., Ltd. Recent Development
11.18 BerGenBio
11.18.1 BerGenBio Company Detail
11.18.2 BerGenBio Business Overview
11.18.3 BerGenBio Kinase Inhibitors Introduction
11.18.4 BerGenBio Revenue in Kinase Inhibitors Business (2019-2024)
11.18.5 BerGenBio Recent Development
11.19 Rigel Pharmaceuticals
11.19.1 Rigel Pharmaceuticals Company Detail
11.19.2 Rigel Pharmaceuticals Business Overview
11.19.3 Rigel Pharmaceuticals Kinase Inhibitors Introduction
11.19.4 Rigel Pharmaceuticals Revenue in Kinase Inhibitors Business (2019-2024)
11.19.5 Rigel Pharmaceuticals Recent Development
11.20 Mirati Therapeutics
11.20.1 Mirati Therapeutics Company Detail
11.20.2 Mirati Therapeutics Business Overview
11.20.3 Mirati Therapeutics Kinase Inhibitors Introduction
11.20.4 Mirati Therapeutics Revenue in Kinase Inhibitors Business (2019-2024)
11.20.5 Mirati Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
List of Tables
Table 1. Global Kinase Inhibitors Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Non-receptor Tyrosine Kinase Inhibitors
Table 3. Key Players of Receptor Tyrosine Kinase Inhibitors
Table 4. Key Players of Multikinase Inhibitors
Table 5. Key Players of Serine/Threonine Kinase Inhibitors
Table 6. Key Players of Protein Kinase C Inhibitors
Table 7. Key Players of RHO Kinase Inhibitors
Table 8. Key Players of Others
Table 9. Global Kinase Inhibitors Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 10. Global Kinase Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 11. Global Kinase Inhibitors Market Size by Region (2019-2024) & (US$ Million)
Table 12. Global Kinase Inhibitors Market Share by Region (2019-2024)
Table 13. Global Kinase Inhibitors Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 14. Global Kinase Inhibitors Market Share by Region (2025-2030)
Table 15. Kinase Inhibitors Market Trends
Table 16. Kinase Inhibitors Market Drivers
Table 17. Kinase Inhibitors Market Challenges
Table 18. Kinase Inhibitors Market Restraints
Table 19. Global Kinase Inhibitors Revenue by Players (2019-2024) & (US$ Million)
Table 20. Global Kinase Inhibitors Market Share by Players (2019-2024)
Table 21. Global Top Kinase Inhibitors Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kinase Inhibitors as of 2023)
Table 22. Ranking of Global Top Kinase Inhibitors Companies by Revenue (US$ Million) in 2023
Table 23. Global 5 Largest Players Market Share by Kinase Inhibitors Revenue (CR5 and HHI) & (2019-2024)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Kinase Inhibitors Product Solution and Service
Table 26. Date of Enter into Kinase Inhibitors Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Kinase Inhibitors Market Size by Type (2019-2024) & (US$ Million)
Table 29. Global Kinase Inhibitors Revenue Market Share by Type (2019-2024)
Table 30. Global Kinase Inhibitors Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 31. Global Kinase Inhibitors Revenue Market Share by Type (2025-2030)
Table 32. Global Kinase Inhibitors Market Size by Application (2019-2024) & (US$ Million)
Table 33. Global Kinase Inhibitors Revenue Market Share by Application (2019-2024)
Table 34. Global Kinase Inhibitors Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 35. Global Kinase Inhibitors Revenue Market Share by Application (2025-2030)
Table 36. North America Kinase Inhibitors Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. North America Kinase Inhibitors Market Size by Country (2019-2024) & (US$ Million)
Table 38. North America Kinase Inhibitors Market Size by Country (2025-2030) & (US$ Million)
Table 39. Europe Kinase Inhibitors Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 40. Europe Kinase Inhibitors Market Size by Country (2019-2024) & (US$ Million)
Table 41. Europe Kinase Inhibitors Market Size by Country (2025-2030) & (US$ Million)
Table 42. Asia-Pacific Kinase Inhibitors Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 43. Asia-Pacific Kinase Inhibitors Market Size by Region (2019-2024) & (US$ Million)
Table 44. Asia-Pacific Kinase Inhibitors Market Size by Region (2025-2030) & (US$ Million)
Table 45. Latin America Kinase Inhibitors Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Latin America Kinase Inhibitors Market Size by Country (2019-2024) & (US$ Million)
Table 47. Latin America Kinase Inhibitors Market Size by Country (2025-2030) & (US$ Million)
Table 48. Middle East & Africa Kinase Inhibitors Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 49. Middle East & Africa Kinase Inhibitors Market Size by Country (2019-2024) & (US$ Million)
Table 50. Middle East & Africa Kinase Inhibitors Market Size by Country (2025-2030) & (US$ Million)
Table 51. Merck Company Detail
Table 52. Merck Business Overview
Table 53. Merck Kinase Inhibitors Product
Table 54. Merck Revenue in Kinase Inhibitors Business (2019-2024) & (US$ Million)
Table 55. Merck Recent Development
Table 56. Novartis Company Detail
Table 57. Novartis Business Overview
Table 58. Novartis Kinase Inhibitors Product
Table 59. Novartis Revenue in Kinase Inhibitors Business (2019-2024) & (US$ Million)
Table 60. Novartis Recent Development
Table 61. Pfizer Company Detail
Table 62. Pfizer Business Overview
Table 63. Pfizer Kinase Inhibitors Product
Table 64. Pfizer Revenue in Kinase Inhibitors Business (2019-2024) & (US$ Million)
Table 65. Pfizer Recent Development
Table 66. Sanofi Company Detail
Table 67. Sanofi Business Overview
Table 68. Sanofi Kinase Inhibitors Product
Table 69. Sanofi Revenue in Kinase Inhibitors Business (2019-2024) & (US$ Million)
Table 70. Sanofi Recent Development
Table 71. GlaxoSmithKline Company Detail
Table 72. GlaxoSmithKline Business Overview
Table 73. GlaxoSmithKline Kinase Inhibitors Product
Table 74. GlaxoSmithKline Revenue in Kinase Inhibitors Business (2019-2024) & (US$ Million)
Table 75. GlaxoSmithKline Recent Development
Table 76. Biogen Idec Company Detail
Table 77. Biogen Idec Business Overview
Table 78. Biogen Idec Kinase Inhibitors Product
Table 79. Biogen Idec Revenue in Kinase Inhibitors Business (2019-2024) & (US$ Million)
Table 80. Biogen Idec Recent Development
Table 81. Bayer Healthcare Pharmaceuticals Company Detail
Table 82. Bayer Healthcare Pharmaceuticals Business Overview
Table 83. Bayer Healthcare Pharmaceuticals Kinase Inhibitors Product
Table 84. Bayer Healthcare Pharmaceuticals Revenue in Kinase Inhibitors Business (2019-2024) & (US$ Million)
Table 85. Bayer Healthcare Pharmaceuticals Recent Development
Table 86. Johnson Company Detail
Table 87. Johnson Business Overview
Table 88. Johnson Kinase Inhibitors Product
Table 89. Johnson Revenue in Kinase Inhibitors Business (2019-2024) & (US$ Million)
Table 90. Johnson Recent Development
Table 91. Tolero Pharmaceutical Company Detail
Table 92. Tolero Pharmaceutical Business Overview
Table 93. Tolero Pharmaceutical Kinase Inhibitors Product
Table 94. Tolero Pharmaceutical Revenue in Kinase Inhibitors Business (2019-2024) & (US$ Million)
Table 95. Tolero Pharmaceutical Recent Development
Table 96. Astellas Pharma Inc Company Detail
Table 97. Astellas Pharma Inc Business Overview
Table 98. Astellas Pharma Inc Kinase Inhibitors Product
Table 99. Astellas Pharma Inc Revenue in Kinase Inhibitors Business (2019-2024) & (US$ Million)
Table 100. Astellas Pharma Inc Recent Development
Table 101. Eli Lilly and Co Company Detail
Table 102. Eli Lilly and Co Business Overview
Table 103. Eli Lilly and Co Kinase Inhibitors Product
Table 104. Eli Lilly and Co Revenue in Kinase Inhibitors Business (2019-2024) & (US$ Million)
Table 105. Eli Lilly and Co Recent Development
Table 106. Incyte Corp Company Detail
Table 107. Incyte Corp Business Overview
Table 108. Incyte Corp Kinase Inhibitors Product
Table 109. Incyte Corp Revenue in Kinase Inhibitors Business (2019-2024) & (US$ Million)
Table 110. Incyte Corp Recent Development
Table 111. AstraZeneca Company Detail
Table 112. AstraZeneca Business Overview
Table 113. AstraZeneca Kinase Inhibitors Product
Table 114. AstraZeneca Revenue in Kinase Inhibitors Business (2019-2024) & (US$ Million)
Table 115. AstraZeneca Recent Development
Table 116. Bristol-Myers Squibb Company Detail
Table 117. Bristol-Myers Squibb Business Overview
Table 118. Bristol-Myers Squibb Kinase Inhibitors Product
Table 119. Bristol-Myers Squibb Revenue in Kinase Inhibitors Business (2019-2024) & (US$ Million)
Table 120. Bristol-Myers Squibb Recent Development
Table 121. Boehringer Ingelheim International GmbH Company Detail
Table 122. Boehringer Ingelheim International GmbH Business Overview
Table 123. Boehringer Ingelheim International GmbH Kinase Inhibitors Product
Table 124. Boehringer Ingelheim International GmbH Revenue in Kinase Inhibitors Business (2019-2024) & (US$ Million)
Table 125. Boehringer Ingelheim International GmbH Recent Development
Table 126. F. Hoffmann-La Roche Ltd Company Detail
Table 127. F. Hoffmann-La Roche Ltd Business Overview
Table 128. F. Hoffmann-La Roche Ltd Kinase Inhibitors Product
Table 129. F. Hoffmann-La Roche Ltd Revenue in Kinase Inhibitors Business (2019-2024) & (US$ Million)
Table 130. F. Hoffmann-La Roche Ltd Recent Development
Table 131. Eisai Co., Ltd. Company Detail
Table 132. Eisai Co., Ltd. Business Overview
Table 133. Eisai Co., Ltd. Kinase Inhibitors Product
Table 134. Eisai Co., Ltd. Revenue in Kinase Inhibitors Business (2019-2024) & (US$ Million)
Table 135. Eisai Co., Ltd. Recent Development
Table 136. BerGenBio Company Detail
Table 137. BerGenBio Business Overview
Table 138. BerGenBio Kinase Inhibitors Product
Table 139. BerGenBio Revenue in Kinase Inhibitors Business (2019-2024) & (US$ Million)
Table 140. BerGenBio Recent Development
Table 141. Rigel Pharmaceuticals Company Detail
Table 142. Rigel Pharmaceuticals Business Overview
Table 143. Rigel Pharmaceuticals Kinase Inhibitors Product
Table 144. Rigel Pharmaceuticals Revenue in Kinase Inhibitors Business (2019-2024) & (US$ Million)
Table 145. Rigel Pharmaceuticals Recent Development
Table 146. Mirati Therapeutics Company Detail
Table 147. Mirati Therapeutics Business Overview
Table 148. Mirati Therapeutics Kinase Inhibitors Product
Table 149. Mirati Therapeutics Revenue in Kinase Inhibitors Business (2019-2024) & (US$ Million)
Table 150. Mirati Therapeutics Recent Development
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Kinase Inhibitors Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Kinase Inhibitors Market Share by Type: 2023 VS 2030
Figure 3. Non-receptor Tyrosine Kinase Inhibitors Features
Figure 4. Receptor Tyrosine Kinase Inhibitors Features
Figure 5. Multikinase Inhibitors Features
Figure 6. Serine/Threonine Kinase Inhibitors Features
Figure 7. Protein Kinase C Inhibitors Features
Figure 8. RHO Kinase Inhibitors Features
Figure 9. Others Features
Figure 10. Global Kinase Inhibitors Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 11. Global Kinase Inhibitors Market Share by Application: 2023 VS 2030
Figure 12. Oncology Case Studies
Figure 13. Inflammatory Diseases Case Studies
Figure 14. Others Case Studies
Figure 15. Kinase Inhibitors Report Years Considered
Figure 16. Global Kinase Inhibitors Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 17. Global Kinase Inhibitors Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 18. Global Kinase Inhibitors Market Share by Region: 2023 VS 2030
Figure 19. Global Kinase Inhibitors Market Share by Players in 2023
Figure 20. Global Top Kinase Inhibitors Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kinase Inhibitors as of 2023)
Figure 21. The Top 10 and 5 Players Market Share by Kinase Inhibitors Revenue in 2023
Figure 22. North America Kinase Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. North America Kinase Inhibitors Market Share by Country (2019-2030)
Figure 24. United States Kinase Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Canada Kinase Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Kinase Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe Kinase Inhibitors Market Share by Country (2019-2030)
Figure 28. Germany Kinase Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. France Kinase Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. U.K. Kinase Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Italy Kinase Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Russia Kinase Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Nordic Countries Kinase Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Kinase Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Kinase Inhibitors Market Share by Region (2019-2030)
Figure 36. China Kinase Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Japan Kinase Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. South Korea Kinase Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Southeast Asia Kinase Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. India Kinase Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Australia Kinase Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Kinase Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America Kinase Inhibitors Market Share by Country (2019-2030)
Figure 44. Mexico Kinase Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Brazil Kinase Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Kinase Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Kinase Inhibitors Market Share by Country (2019-2030)
Figure 48. Turkey Kinase Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Saudi Arabia Kinase Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Merck Revenue Growth Rate in Kinase Inhibitors Business (2019-2024)
Figure 51. Novartis Revenue Growth Rate in Kinase Inhibitors Business (2019-2024)
Figure 52. Pfizer Revenue Growth Rate in Kinase Inhibitors Business (2019-2024)
Figure 53. Sanofi Revenue Growth Rate in Kinase Inhibitors Business (2019-2024)
Figure 54. GlaxoSmithKline Revenue Growth Rate in Kinase Inhibitors Business (2019-2024)
Figure 55. Biogen Idec Revenue Growth Rate in Kinase Inhibitors Business (2019-2024)
Figure 56. Bayer Healthcare Pharmaceuticals Revenue Growth Rate in Kinase Inhibitors Business (2019-2024)
Figure 57. Johnson Revenue Growth Rate in Kinase Inhibitors Business (2019-2024)
Figure 58. Tolero Pharmaceutical Revenue Growth Rate in Kinase Inhibitors Business (2019-2024)
Figure 59. Astellas Pharma Inc Revenue Growth Rate in Kinase Inhibitors Business (2019-2024)
Figure 60. Eli Lilly and Co Revenue Growth Rate in Kinase Inhibitors Business (2019-2024)
Figure 61. Incyte Corp Revenue Growth Rate in Kinase Inhibitors Business (2019-2024)
Figure 62. AstraZeneca Revenue Growth Rate in Kinase Inhibitors Business (2019-2024)
Figure 63. Bristol-Myers Squibb Revenue Growth Rate in Kinase Inhibitors Business (2019-2024)
Figure 64. Boehringer Ingelheim International GmbH Revenue Growth Rate in Kinase Inhibitors Business (2019-2024)
Figure 65. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Kinase Inhibitors Business (2019-2024)
Figure 66. Eisai Co., Ltd. Revenue Growth Rate in Kinase Inhibitors Business (2019-2024)
Figure 67. BerGenBio Revenue Growth Rate in Kinase Inhibitors Business (2019-2024)
Figure 68. Rigel Pharmaceuticals Revenue Growth Rate in Kinase Inhibitors Business (2019-2024)
Figure 69. Mirati Therapeutics Revenue Growth Rate in Kinase Inhibitors Business (2019-2024)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
